Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report).

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.27%.

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the December 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

Recently, VRTX broke through the 20-day moving average, which suggests a short-term bullish trend. The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's ...